Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study

Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is the newest cystic fibrosis transmembrane conductance regulator (CFTR) modulator drug approved for the treatment of patients with cystic fibrosis (pwCF) aged ≥6 years with at least one copy of the F508del mutation (F) in the CFTR gene or another m...

Descripción completa

Detalles Bibliográficos
Autores principales: Carnovale, Vincenzo, Iacotucci, Paola, Terlizzi, Vito, Colangelo, Carmela, Ferrillo, Lorenza, Pepe, Angela, Francalanci, Michela, Taccetti, Giovanni, Buonaurio, Serena, Celardo, Assunta, Salvadori, Laura, Marsicovetere, Giovanni, D’Andria, Michele, Ferrara, Nicola, Salvatore, Donatello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876133/
https://www.ncbi.nlm.nih.gov/pubmed/35207295
http://dx.doi.org/10.3390/jcm11041021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876133/
https://www.ncbi.nlm.nih.gov/pubmed/35207295
http://dx.doi.org/10.3390/jcm11041021

Ejemplares similares